Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 50

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 14
Chunk 50
---
    12,068

    10,881

    Operating lease right-of-use assets

    43,507

    46,549

    Investment in Radionetics

    —

    470

    Restricted cash, net of current portion

    800

    1,300

    Other assets

    2,829

    2,000

    Total assets
     
    $
    1,434,592

    $
    635,353

    Liabilities and Stockholders’ Equity

    Current liabilities:

    Accounts payable and accrued expenses
     
    $
    21,469

    $
    23,196

    Accrued compensation and related expenses

    28,887

    14,517

    Deferred revenue

    2,176

    2,056

    Operating lease liabilities

    7,152

    4,173

    Total current liabilities

    59,684

    43,942

    Operating lease liabilities, non-current

    44,570

    47,555

    Deferred revenue, non-current

    4,704

    4,750

    Other non-current liabilities

    829

    —

    Total liabilities

    109,787

    96,247

    Commitments and contingencies (Note 7)

    Stockholders’ equity:

    Preferred stock, $0.001 par; 10,000 shares authorized, no shares   issued or outstanding at December 31, 2024 or 2023

    —

    —

    Common stock and paid-in capital, $0.001 par; 200,000 shares authorized,   92,926 shares issued and outstanding at December 31, 2024;  68,175 shares issued and outstanding at December 31, 2023

    2,275,952

    1,191,831

    Accumulated other comprehensive income (loss)

    963

    977

    Accumulated deficit

    (952,110
    )

    (653,702
    )

    Total stockholders’ equity

    1,324,805

    539,106

    Total liabilities and stockholders’ equity
     
    $
    1,434,592

    $
    635,353

See the accompanying notes to these